Swiss Biotech Report – biotech industry continues to thrive

The Swiss biotech industry increased its sales, exports and research investments once again in 2018, as indicated by the Swiss Biotech Report 2019 (BTR). The industry’s growth is largely due to investment in research and development, which rose by 32 per cent from 2017 to 2018.

 

This is also reflected in the patent portfolio with 53 per cent of Swiss biotech patents classified as world-class patents. In addition, according to the authors of the report, the pipeline of companies is filled with promising drug candidates in the preclinical and clinical research phase.

 

The Swiss Federal Institute of Intellectual Property (IPI) is represented in the Steering Committee of the report. In an article, IPI experts explore how patent landscape analyses can visualise trends in biotechnology.